ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.
Molecules | Free Full-Text | Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor asciminib (ABL001)
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
Efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia | Faculty of Sciences, Engineering and Technology | University of Adelaide
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
ABL001 - GME
GME Antenna Base Universal with 4.5m Coaxial & PL259 - ABL001 - Accessories | Repco New Zealand
A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram